American Society of Hirudotherapy

Isolation, Characterization, and Evaluation of a Lytic Jumbo Phage Z90 Againstin American Eels ().

Research article published in Antibiotics (Basel, Switzerland) (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportAntimicrobial ResistanceGenomics & ProteomicsSafety & Infection ControlZhang M et al. · Antibiotics (Basel, Switzerland), 2025

Abstract

Background:Aeromonas hydrophila is a common bacterial pathogen that causes hemorrhagic septicaemia in several farmed aquaculture species. Phage therapy is considered a promising and feasible alternative to antibiotic treatment. Methods: In this study, an A. hydrophila-infecting jumbo phage Z90 was isolated from an aquaculture pond. The biological characteristics, genomic features, and in vitro and in vivo experiments were investigated to evaluate its application potential. Results: Phage Z90 was a myovirus with distinctive curled tail fibers. Additionally, phylogenetic and genomic analyses found that the phage Z90 was a novel virus belonging to the genus Ferozepurvirus of the family Chimalliviridae. One-step growth curve analysis revealed that the phage Z90 was a lytic phage, exhibiting a short latency period of 20 min and a relatively large burst size of 270 ± 42 PFU/cell. The phage Z90 particles were stable at psychrotrophic and mesophilic temperatures (10-50 °C) and a wide range of pH (pH 3-12). Genomic analysis revealed that the phage Z90 did not contain any genes encoding toxins, virulence factors, or antibiotic resistance factors. In vivo analysis demonstrated that the phage Z90 protected American eels from A. hydrophila infection, greatly increasing eel survival rates and alleviating symptoms caused by bacterial infections. The comparison of different phage administration methods suggested that phage Z90 was better administered through intraperitoneal injection than immersion in aquaculture water. Moreover, the combination of phage Z90 and ampicillin improved the bactericidal effect and reduced the treatment dosage compared to antibiotics or phage alone. Conclusions: Altogether, the findings of this study indicate that the phage Z90 can serve as a promising biocontrol agent for the treatment of A. hydrophila infection in aquaculture.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

is a common bacterial pathogen that causes hemorrhagic septicaemia in several farmed aquaculture species. Phage therapy is considered a promising and feasible alternative to antibiotic treatment.

Why This Matters for Hirudotherapy

This study isolated a lytic jumbo bacteriophage (Z90) active against Aeromonas hydrophila, a pathogen causing hemorrhagic septicaemia in aquaculture, and characterized it as a novel myovirus stable across a broad temperature (10-50 C) and pH (3-12) range and free of toxin, virulence, or antibiotic-resistance genes; in vivo it improved survival of A. hydrophila-infected American eels, worked best by intraperitoneal injection, and enhanced bactericidal effect when combined with ampicillin. The connection to hirudotherapy is tangential and infection-control-oriented: A. hydrophila and related Aeromonas species are gut symbionts of medicinal leeches and a recognized source of post-leech-therapy wound infection, so phage-based control of this pathogen is conceptually relevant to managing that risk. However, this is a preclinical phage-therapy study in fish with no leech, no human, and no hirudotherapy data, and it should not be presented as evidence about leech-therapy infection management in patients.

Citation

Isolation, Characterization, and Evaluation of a Lytic Jumbo Phage Z90 Againstin American Eels ().

Zhang M et al. · Antibiotics (Basel, Switzerland), 2025

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.